	US 11,898,169 B2
	Synergistic genome-nonintegrating reprogramming by microRNAs and transcription factors
Kwang-Soo Kim, Lexington, MA (US); and Young Cha, Lexington, MA (US)
Assigned to The McLean Hospital Corporation, Belmont, MA (US)
Filed by The McLean Hospital Corporation, Belmont, MA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/239,059.
Application 17/239,059 is a continuation of application No. 15/036,235, granted, now 11,001,809, previously published as PCT/US2014/065371, filed on Nov. 13, 2014.
Claims priority of provisional application 61/904,934, filed on Nov. 15, 2013.
Prior Publication US 2021/0238556 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/074 (2010.01); C12N 15/113 (2010.01); A61K 35/12 (2015.01)

CPC C12N 5/0696 (2013.01) [A61K 35/12 (2013.01); C12N 15/113 (2013.01); C12N 2310/141 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/65 (2013.01); C12N 2506/1307 (2013.01); C12N 2510/00 (2013.01); C12N 2799/022 (2013.01)]

21 Claims

1. A method of generating mammalian patient-specific induced pluripotent stem cells for treating a patient, comprising:

providing a quantity of mammalian somatic or non-embryonic cells from the patient;

contacting the mammalian somatic or non-embryonic cells with a quantity of one or more reprogramming factors and one or more microRNA molecules; and

culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell,

wherein the one or more microRNA molecules consist of (i) at least one miR-302 cluster member and (ii) at least one miR-200 cluster member, and

wherein the quantity of reprogramming factors comprises at least Oct-4, Sox-2, Klf-4, and at least one of c-Myc or 1-Myc.